Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Jun

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC

PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer

Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases

Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows

Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC